DNM1L and Huntington disease: Reduction of Drp1 GTPase activity can rescue mHTT-mediated mitochondrial fragmentation and defects in anterograde and retrograde mitochondrial movement and neuronal death, suggesting that Drp1 may represent a suitable target for HD therapy (Song et al., 2011).